PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza
Professional Postgraduate Services® (PPS®), renowned for its award-winning healthcare websites, announces a two-part, live CME/CE webcast series on RSV
and pediatric influenza, Preventing and Managing RSV
Disease and Influenza Disease in Your Pediatric Practice, now available on Pediatric...
St. Jude Finds Risk Factors for Severe RSV Infection in Immunocompromised Children
Children receiving treatment for cancer who are under 2 years and those
with very low levels of immune system cells called lymphocytes are at
higher risk for severe respiratory syncytial virus related disease
MEMPHIS, Tenn., Feb. 4 /PRNewswire-USNewswire/ -- St. Jude Children's
St. Jude finds risk factors for severe RSV infection in immunocompromised children
St. Jude Childrens Research Hospital investigators and collaborators have shown how to predict if a child who is infected with respiratory syncytial virus (RSV) while being treated for cancer or another catastrophic disease is at high risk for developing severe infection. The finding will help cli...
MedImmune to present RSV surveillance and cost-effectiveness data at American Academy of Pediatrics
SAN FRANCISCO, October 26, 2007 MedImmune, Inc. today announced it will present three abstracts at the American Academy of Pediatrics (AAP) 2007 National Conference & Exhibition, adding to the companys growing body of research into the prevention of respiratory syncytial virus (RSV), a leading ca...
Medimmune announces phase 2 safety data for anti-RSV antibody and national RSV surveillance results
SAN DIEGO, October 4, 2007 MedImmune, Inc. today announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting adding to the body of knowledge about respiratory syncytial virus (RSV). RSV
is a viral pathogen that produces ann...
MedImmune presents new pharmaco-economic data at AAP regarding infants at high risk for RSV
SAN FRANCISCO, October 29, 2007 MedImmune today announced results from a recent economic analysis of Synagis (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high-risk inf...
Parental Knowledge Of RSV Infections Is Vital
Respiratory syncytial virus (RSV) is one of the primary diseases affecting the children below two years. It is prevalent during the winter seasons. RSV
infections start by the end of November and the incidence increases and reaches a peak by the month of December. //
Deborah Lehman, MD, associat...
Physicians To Discuss Ways To Save Premature Babies From RSV
Physicians from across the world are gathering for National Association of Neonatal Nurses Lead Media Teleconference, USA, to review that data and discuss ways of preventing occurrence of RSV
to premature babies. //
More than 300,000 premature infants are born prior to 36 weeks gestation each ...
MedImmune Expands Access for Eligible Premature Infants to Receive Synagis(R) at No Cost
...re information about the help that's available for rsv
prevention and treatment can be found by visiting ...usually in the thigh muscle, each month during the rsv
season. Children who develop an rsv
infection while receiving Synagis should continue ...
First of its kind study identifies risk factors for LRTIs in Inuit children
... (RSV) the most common cause of lower respiratory tract infections. The vaccine is used only for prevention and is usually a monthly injection during rsv
The results demonstrated that by immunizing rural Inuit infants with the vaccine, the health care system could save money up to $8,000 per...
RSV in Medical Technology
MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
Prospective Study Seeks to Assess RSV
Burden in Outpatient Setting During First Year of Life; Reinforcing Commitment to Pediatric Research
GAITHERSBURG, Md., June 29 /PRNewswire/ -- MedImmune continues to advance its commitment to pediatric research with today's announcement of the first ob...
MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
Results Showing Burden of RSV
Disease Presented at Pediatric Academic Societies' Annual Meeting
BALTIMORE, May 5 /PRNewswire/ -- MedImmune today announced results from a recent study it sponsored, performed by the Kaiser Permanente Division of Research in Oakland, CA, assessing risk factors f...
MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
- Data Presented at Infectious Diseases Society of America (IDSA) 45TH Annual Meeting -
SAN DIEGO, Oct. 4 /PRNewswire/ -- MedImmune, Inc. today announced
results from two important studies presented at the 2007 Infectious
Diseases Society of America (IDSA) 45th Annu...
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today
announced that in a Phase 3 study, motavizumab was shown to reduce
hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as
compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in
MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
SAN FRANCISCO, Oct. 29 /PRNewswire/ -- MedImmune today announced
results from a recent economic analysis of Synagis(R) (palivizumab), a
monoclonal antibody (MAb) that is the standard of care for prevention of
severe lower respiratory tract infection due to respiratory syncytial virus
(RSV) in ...
MedImmune Announces Positive Clinical Results at PAS Annual Meeting
From Large Prospective Trial in Prevention of Serious RSV Disease
- Numax Achieves Primary Endpoint Among High-Risk Infants Versus
Current Standard of Care and Shows Reduction of Medically Attended
Outpatient RSV- Related Lower Respiratory Infections -
TORONTO, May 08, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc.
today announced positive results from a large p...
Novavax Announces Preclinical Data for Respiratory Syncytial Virus Vaccine Candidate
... Novavax's first vaccine candidate for the prevention of rsv
ROCKVILLE, Md., Dec. 8 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX ) announced today that Dr. Trudy Morrison, PhD, Professor of M...
MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
...vere respiratory syncytial virus (RSV) infections. rsv
the most common respiratory infection in infant...the National
Institutes of Health, to help address rsv
disease in children. The vaccine
was originally de...ins, Ph.D. and Brian R. Murphy, M.D.
is the most important cause of viral lower respira...
Study Shows Physician Judgment is Important in Reducing Rate of RSV-Related Hospitalizations Among High-Risk Infants
...yncytial virus (RSV) disease in high-risk infants. rsv
leading cause of viral respiratory infection .... Fifty percent of those
infants received Synagis. rsv
prophylaxis was requested, but not
administered in... of these infants. This group was found to
have an rsv
hospitalization rate of 8.3 percent, which was alm...
Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
...d that motavizumab reduced
hospitalizations due to rsv
by 83 percent as compared to placebo (8.3
percent ...SV. This study confirmed the high rates of serious rsv
this population. An interim analysis, r...al evidence
demonstrating that motavizumab reduced rsv
hospitalizations and LRIs
requiring outpatient med...
RSV in Medical Products
Clearview RSV Test Kit
Description: Clearview RSV
is a simple, immunochromatographic assay to aid in the diagnosis of respiratory syncytial virus (RSV) infections in children less than 6 years and adults over age 60....
Company:Inverness Point of Care
NOW RSV Test
Description: The NOW RSV
Test is one of the easiest tests to run on the market today. Rapid results are available in 15 minutes with no hands-on time. Critical care instructions can be provided to parents prior to the child leaving the pediatrician's office and valuable information can be obtained prior to hosp...
Company:Inverness Point of Care
SAS RSV Test Kit
Description: The SAS RSV
antigen test is a visual and rapid assay for the presumptive qualitative detection of Respitory Syncytial(RSV) antigen directly from nasopharyngeal specimens in neonatal and pediatric patients. This one-step 15 minute test has a built-in procedural control and can be stored at room temp...
ImmunoCard STAT!® RSV PLUS
Description: Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Company:Meridian Bioscience, Inc.
PathoDx RSV Kit
Description: Immunofluorescence test for detecting RSV
in direct specimens and cultures....
BD Directigen RSV Test
Description: BD Directigen RSV
Test fast, easy and accurate, its truly STAT. And it will help your laboratory quickly and confidently support critical antiviral therapy recommendations....
Company:BD Diagnostic Systems
Fisher Sure-Vue RSV Test Kit
Description: Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
ImmunoCard STAT!® RSV
Description: One step Immunochromatographic Assay for the detection of Respiratory Syncytial Virus...
Company:Meridian Bioscience, Inc.
Description: IFA for the direct detection of Respiratory Syncytial Virus (RSV)...
Company:Meridian Bioscience, Inc.
Description: Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
RSV in Medical Dictionary
...t rate that is faster than normal. ... Cocaine abuse and alcohol withdrawal are other causes of rapid heartbeat . ... Rapid Heartbeat . rsv
Infection. Slow Heartbeat . Sudden Infant Death Syndrome. Vomiting ... That is, they alternate rapid breathing with slow breathing. This ... ...
...er HL, Del Mar C. Immunoglobulin treatment for respiratory syncytial virus infection. ... This review assesses immunoglobulin treatment of rsv
infection ... Immunoglobulin deficiency syndromes are a group of disorders that involve ... All classes of immunoglobulin antibodies are d...
RSV in Biological News
Novel antiviral technology inhibits RSV infection in mice
A novel antiviral treatment combining
nanoparticle and gene silencing technologies thwarts attacks of
respiratory syncytial virus (RSV) -- a virus associated with severe
bronchitis and asthma, an animal study by University of South Florida
researchers found. The study was reported in the January 20...
RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report
...Medical Center researchers, however, suggests that rsv
may hide in the lungs even after other symptoms ab...ecurrent wheezing due to a virus such as RSV."
is the leading cause of viral respiratory infectio... children worldwide. Half of all babies develop an rsv
infection within the first year of life and practi...
Tips from the Journals of the American Society for Microbiology
...r nearly as effective (more than 95%) as the cell culture, or gold standard, in both sensitivity and specificity. Only test results for rhinovirus and rsv
came in under 95%. In addition, compared to the RSV-specific ICA, the RespiFinder showed a specificity and sensitivity of approximately 80%.
RNA interference therapy heals growth deficiency disorder in a live animal
...eveloping highly targeted therapies for a number of genetic diseases including macular degeneration in the eye and to block viruses such as herpes and rsv
respiratory viruses. To the best of our knowledge, this is the first time it has been used to correct a dominant negative disorder in a living animal,...
Scientists find predisposition to bronchiolitis in some babies
Bronchiolitis frequently develops in infants suffering from respiratory syncytial virus (RSV) infection. Although most infants infected with rsv
have only mild symptoms such as a cough and wheeze some develop potentially life-threatening bronchiolitis. Babies born prematurely are particularly s...
UQ research heralds vaccine technology breakthrough
...earch centre director Professor Robert Tindle said rsv
cost millions of dollars a year in health care in ...as prevent against it.
Those most at risk from rsv
are children aged two and under, especially those ...s of life.
The mature paediatric market for an rsv
vaccine has been estimated at approximately US$800...
RNAi shows promise in gene therapy, Stanford researcher says
...the viruses that cause hepatitis and HIV in mice.
With three human RNAi gene therapy trials now under way - two in macular degeneration and one in rsv
pneumonia - the technique Kay pioneered may be among the first to find widespread use for treating human diseases. "We've worked on a gene therapeut...
Silver bullet: UGA researchers use laser, nanotechnology to rapidly detect viruses
...g nanotechnology, a team of University of Georgia researchers has developed a diagnostic test that can detect viruses as diverse as influenza, HIV and rsv
in 60 seconds or less.
In addition to saving time, the technique ?which is detailed in the November issue of the journal Nano Letters ?could save li...
Flu not the only germ threat this time of year
...that from flu. Even though flu gets all the press, rsv
is a stealth bug worthy of attention too.
Ann F...nit of the Department of Medicine, have found that rsv
affects elderly and high-risk adults as much as th... elderly and high-risk adults die annually from an rsv
infection, and that the bug is responsible for mor...
Biota makes major antiviral discovery
...ass of orally-effective, potent antivirals against rsv
(respiratory syncytial virus) infection. Biota has...ical development prior to human clinical trials.
infection is an important medical need and already...ients: premature infants. If successful, the Biota rsv
drug is expected to have significant advantages an...
RSV in Biological Technology
MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
BOSTON, Oct. 11 /PRNewswire-USNewswire/ -- MedImmune announced today it
will present four abstracts at the American Academy of Pediatrics (AAP)
2008 National Conference & Exhibition that add to the company's growing
body of research into the prevention of respiratory syncytial virus (RSV),
MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
SAN FRANCISCO, Oct. 26 /PRNewswire/ -- MedImmune, Inc. today announced
it will present three abstracts at the American Academy of Pediatrics (AAP)
2007 National Conference & Exhibition, adding to the company's growing body
of research into the prevention of respiratory syncytial virus (RSV), a...
Aktiv-Dry Awarded Research Grant to Explore Inhalable siRNA Dry Powder Targeting RSV
BOULDER, Colo., Nov. 12 /PRNewswire/ -- Aktiv-Dry LLC has been awarded
an SBIR research grant from the Center for Disease Control and Prevention
(CDC) to explore the formulation of certain siRNA products as inhalable dry
powders that might eventually be used to treat pulmonary disorders such a...
Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
...announced, Novavax has been evaluating a number of rsv
vaccine candidates, all of which have successfully...idate which has been shown to protect mice against rsv
disease and can be produced at sufficient yields t... the vaccine protected mice against replication of rsv
in the lungs. The study included groups of mice t...
Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
...In addition, Mr. Trizzino's responsibilities at MedImmune and work with the rsv
(Respiratory Syncytial Virus) market should be most valuable to Novavax as we continue development of our own rsv
vaccine. I am excited to have him join our Company and look forward to his...
NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate Directed Against the Fusion (F) Protein
...ix (i.e., "core") protein decorated with the human rsv
F protein. The VLPs mimic the three-dimensional structure of rsv
but cannot replicate and cause disease because the...responses observed with either live or inactivated rsv
immunization. The VLPs induced strong cell mediat...
NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus ('RSV') Vaccine Candidate
first recombinant VLP for the prevention of rsv
The preclinical study evaluated t... of Newcastle Disease Virus decorated with a human rsv
glycoprotein (Ga), which is important f... mice were immunized with one of four doses of the rsv
candidate, inactivated RSV, live RSV, ...
Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
...on: Evidence for T-Lymphocyte Independent Antibody Responses in Primary rsv
Infection, publication page A190)-Sunday, May 18 from 8:15 a.m. - 4:15 ...jury (Poster Session: Role for Alveolar Macrophages in Limiting Primary rsv
Immunopathology, publication page A623) - Tuesday, May 20 from 8:15 ...
Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
... (H1,2008) Measles and rsv
Phase I Phase I in children ...clinical development and funding are pending.
The program for measles and rsv
will be tested up to and through
clinical Phase I, where it is expected tha...
MedImmune Submits Biologics License Application to FDA for Motavizumab
...help reinforce the positive role
that MAbs play in rsv
prevention within the current clinical body of
evi...ce. It also reinforces our position as a leader in rsv
said Genevieve Losonsky, M.D., vice p...ident, clinical development,
is a leading cause of viral respiratory infection ...